Results 131 to 140 of about 760,023 (268)

Closed-system automated microdistillation of small-volume water samples for tritium and stable isotope analysis. [PDF]

MethodsX
Butera DK, Wassenaar LI, Lapp A, Middlestead P, Warr O.   +4 more
europepmc   +1 more source

Closed-system transfer device use with oncology biologics: A survey of Canadian healthcare practitioners. [PDF]

J Oncol Pharm Pract, 2022
Khaira M, Guy AL.
europepmc   +1 more source

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

Molecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata, Koji Ando, Hirofumi Hasuda, Koshi Mimori, Elizabeth C. Unan, Siddhartha Pulukuri, Aahana Tiku, Allison Berger, Eiji Oki, Ajit Bharti, Tomoharu Yoshizumi   +10 more
wiley   +1 more source

Validation of chemotherapy drug vapor containment of an air cleaning closed-system drug transfer device. [PDF]

J Oncol Pharm Pract, 2022
Levin G, Sessink PJ.
europepmc   +1 more source

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

Molecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary, Jose Javier Bravo‐Cordero   +1 more
wiley   +1 more source

Evaluation of three barrier-type closed system transfer devices using the 2015 NIOSH vapor containment performance draft protocol. [PDF]

Drugs Ther Perspect, 2022
Szkiladz A, Hegner S.
europepmc   +1 more source

Circulating tumor cell viability during and after radiotherapy mirrors treatment response in cancer patients

Molecular Oncology, EarlyView.
Radiotherapy (RT) response depends on the DNA repair capacity of tumor and host cells. We show that circulating tumor cell (CTC) counts and apoptosis rates before and after RT predict treatment response and outcome, which can be accessed via easily accessible liquid biopsy approaches. Created in BioRender. Wikman, H.
Yvonne Goy, Jana Löptien, Cornelia Coith, Afroditi Nanou, Katharina Hintelmann, Pinnschmidt Hans, Cordula Petersen, Klaus Pantel, Sabine Riethdorf, Kerstin Borgmann, Harriet Wikman   +10 more
wiley   +1 more source

A twenty-eight-day evaluation of cytotoxic drug vapor containment in drug-binding closed-system transfer device. [PDF]

Front Public Health
Navarro D, Epstein D.
europepmc   +1 more source

Characterization of volatile compounds of Pixian Douban fermented in closed system of gradient steady-state temperature field. [PDF]

Food Sci Nutr, 2021
Ding W, Liu Y, Zhao X, Peng C, Ye X, Che Z, Liu Y, Liu P, Lin H, Huang J, Xu M.   +10 more
europepmc   +1 more source

Clinical performance of the urine‐based TERT promoter AbsoluteQ Digital PCR for non‐invasive detection of bladder cancer

Molecular Oncology, EarlyView.
A urine‐based digital PCR assay targeting two hotspot TERT promoter variants detected bladder cancer with high sensitivity and no false positives in this case–control cohort. The streamlined AbsoluteQ workflow outperformed Sanger sequencing and supports non‐invasive molecular testing for bladder cancer detection.
Anna Nykel, Izabela Kubiak, Lena Rutkowska, Żaneta Kasprzyk, Łukasz Kępczyński, Michał Bednarek, Dariusz Sobieraj, Jacek Wilkosz, Piotr Kania, Adam Jędrzejczyk, Bogdan Kałużewski, Agnieszka Gach, Tadeusz Kałużewski   +12 more
wiley   +1 more source